Published on
January 3, 2019
- 15:48 GMT
Shanghai Furen Enters Exclusive Licensing Agreement with AstraZeneca to Develop AZD0364 in China
ERK small molecule inhibitor has potential to address unmet medical need in China SHANGHAI, CHINA, January 3, 2019 /EINPresswire.com/ -- Shanghai Furen Medicine R&D Co. Ltd. (Shanghai Furen) today announced an agreement with AstraZeneca for …
Distribution channels:
Healthcare & Pharmaceuticals Industry
...
